208 related articles for article (PubMed ID: 15483021)
1. Response to paclitaxel, topotecan, and topotecan-cyclophosphamide in children with untreated disseminated neuroblastoma treated in an upfront phase II investigational window: a pediatric oncology group study.
Kretschmar CS; Kletzel M; Murray K; Thorner P; Joshi V; Marcus R; Smith EI; London WB; Castleberry R
J Clin Oncol; 2004 Oct; 22(20):4119-26. PubMed ID: 15483021
[TBL] [Abstract][Full Text] [Related]
2. Efficacy of topotecan and cyclophosphamide given in a phase II window trial in children with newly diagnosed metastatic rhabdomyosarcoma: a Children's Oncology Group study.
Walterhouse DO; Lyden ER; Breitfeld PP; Qualman SJ; Wharam MD; Meyer WH
J Clin Oncol; 2004 Apr; 22(8):1398-403. PubMed ID: 15007087
[TBL] [Abstract][Full Text] [Related]
3. Phase II trial of topotecan administered as 72-hour continuous infusion in children with refractory solid tumors: a collaborative Pediatric Branch, National Cancer Institute, and Children's Cancer Group Study.
Blaney SM; Needle MN; Gillespie A; Sato JK; Reaman GH; Berg SL; Adamson PC; Krailo MD; Bleyer WA; Poplack DG; Balis FM
Clin Cancer Res; 1998 Feb; 4(2):357-60. PubMed ID: 9516923
[TBL] [Abstract][Full Text] [Related]
4. Topotecan by 21-day continuous infusion in children with relapsed or refractory solid tumors: a Children's Oncology Group study.
Hawkins DS; Bradfield S; Whitlock JA; Krailo M; Franklin J; Blaney SM; Adamson PC; Reaman G
Pediatr Blood Cancer; 2006 Nov; 47(6):790-4. PubMed ID: 16435380
[TBL] [Abstract][Full Text] [Related]
5. A phase II study of topotecan with vincristine and doxorubicin in children with recurrent/refractory neuroblastoma.
Garaventa A; Luksch R; Biasotti S; Severi G; Pizzitola MR; Viscardi E; Prete A; Mastrangelo S; Podda M; Haupt R; De Bernardi B
Cancer; 2003 Dec; 98(11):2488-94. PubMed ID: 14635085
[TBL] [Abstract][Full Text] [Related]
6. Response and toxicity to topotecan in sensitive ovarian cancer cases with small residual disease after first-line treatment with carboplatinum and paclitaxel.
Bolis G; Scarfone G; Tateo S; Mangili G; Villa A; Parazzini F
Gynecol Oncol; 2001 Jan; 80(1):13-5. PubMed ID: 11136562
[TBL] [Abstract][Full Text] [Related]
7. Upfront window trial of topotecan in previously untreated children and adolescents with poor prognosis metastatic osteosarcoma: children's Cancer Group (CCG) 7943.
Seibel NL; Krailo M; Chen Z; Healey J; Breitfeld PP; Drachtman R; Greffe B; Nachman J; Nadel H; Sato JK; Meyers PA; Reaman GH
Cancer; 2007 Apr; 109(8):1646-53. PubMed ID: 17334983
[TBL] [Abstract][Full Text] [Related]
8. Improved response in high-risk neuroblastoma with protracted topotecan administration using a pharmacokinetically guided dosing approach.
Santana VM; Furman WL; Billups CA; Hoffer F; Davidoff AM; Houghton PJ; Stewart CF
J Clin Oncol; 2005 Jun; 23(18):4039-47. PubMed ID: 15961757
[TBL] [Abstract][Full Text] [Related]
9. Intensive therapy with growth factor support for patients with Ewing tumor metastatic at diagnosis: Pediatric Oncology Group/Children's Cancer Group Phase II Study 9457--a report from the Children's Oncology Group.
Bernstein ML; Devidas M; Lafreniere D; Souid AK; Meyers PA; Gebhardt M; Stine K; Nicholas R; Perlman EJ; Dubowy R; Wainer IW; Dickman PS; Link MP; Goorin A; Grier HE; ; ;
J Clin Oncol; 2006 Jan; 24(1):152-9. PubMed ID: 16382125
[TBL] [Abstract][Full Text] [Related]
10. Differential impact of high-dose cyclophosphamide, topotecan, and vincristine in clinical subsets of patients with chemoresistant neuroblastoma.
Kushner BH; Kramer K; Modak S; Qin LX; Cheung NK
Cancer; 2010 Jun; 116(12):3054-60. PubMed ID: 20564411
[TBL] [Abstract][Full Text] [Related]
11. Front-line paclitaxel and topotecan chemotherapy in advanced or metastatic non-small-cell lung cancer: a phase II trial.
Stathopoulos GP; Katis C; Tsavdaridis D; Dimitroulis J; Karaindros D; Stathopoulos J; Dimou E
Cancer Chemother Pharmacol; 2006 Oct; 58(4):555-60. PubMed ID: 16520987
[TBL] [Abstract][Full Text] [Related]
12. Oral topotecan in children with recurrent or progressive high-grade glioma: a Phase I/II study by the German Society for Pediatric Oncology and Hematology.
Wagner S; Erdlenbruch B; Längler A; Gnekow A; Kühl J; Albani M; Völpel S; Bucsky P; Emser A; Peters O; Wolff JE
Cancer; 2004 Apr; 100(8):1750-7. PubMed ID: 15073866
[TBL] [Abstract][Full Text] [Related]
13. Topotecan and cyclophosphamide in patients with refractory or relapsed Ewing tumors.
Hunold A; Weddeling N; Paulussen M; Ranft A; Liebscher C; Jürgens H
Pediatr Blood Cancer; 2006 Nov; 47(6):795-800. PubMed ID: 16411206
[TBL] [Abstract][Full Text] [Related]
14. Weekly administration of topotecan-paclitaxel as second-line treatment in ovarian cancer.
Stathopoulos GP; Malamos NA; Aravantinos G; Rigatos S; Christodoulou Ch; Stathopoulos J; Skarlos D
Cancer Chemother Pharmacol; 2007 Jun; 60(1):123-8. PubMed ID: 17111119
[TBL] [Abstract][Full Text] [Related]
15. Results of induction chemotherapy in children older than 1 year with a stage 4 neuroblastoma treated with the NB 97 French Society of Pediatric Oncology (SFOP) protocol.
Valteau-Couanet D; Michon J; Boneu A; Rodary C; Perel Y; Bergeron C; Rubie H; Coze C; Plantaz D; Bernard F; Chastagner P; Bouzy J; Hartmann O
J Clin Oncol; 2005 Jan; 23(3):532-40. PubMed ID: 15659499
[TBL] [Abstract][Full Text] [Related]
16. Disseminated neuroblastoma in children older than one year at diagnosis: comparable results with three consecutive high-dose protocols adopted by the Italian Co-Operative Group for Neuroblastoma.
De Bernardi B; Nicolas B; Boni L; Indolfi P; Carli M; Cordero Di Montezemolo L; Donfrancesco A; Pession A; Provenzi M; di Cataldo A; Rizzo A; Tonini GP; Dallorso S; Conte M; Gambini C; Garaventa A; Bonetti F; Zanazzo A; D'Angelo P; Bruzzi P;
J Clin Oncol; 2003 Apr; 21(8):1592-601. PubMed ID: 12697885
[TBL] [Abstract][Full Text] [Related]
17. Phase II randomized comparison of topotecan plus cyclophosphamide versus topotecan alone in children with recurrent or refractory neuroblastoma: a Children's Oncology Group study.
London WB; Frantz CN; Campbell LA; Seeger RC; Brumback BA; Cohn SL; Matthay KK; Castleberry RP; Diller L
J Clin Oncol; 2010 Aug; 28(24):3808-15. PubMed ID: 20660830
[TBL] [Abstract][Full Text] [Related]
18. Phase II study on the effect of disease sites, age, and prior therapy on response to iodine-131-metaiodobenzylguanidine therapy in refractory neuroblastoma.
Matthay KK; Yanik G; Messina J; Quach A; Huberty J; Cheng SC; Veatch J; Goldsby R; Brophy P; Kersun LS; Hawkins RA; Maris JM
J Clin Oncol; 2007 Mar; 25(9):1054-60. PubMed ID: 17369569
[TBL] [Abstract][Full Text] [Related]
19. Phase II study of topotecan in combination with dexamethasone, asparaginase, and vincristine in pediatric patients with acute lymphoblastic leukemia in first relapse.
Hijiya N; Stewart CF; Zhou Y; Campana D; Coustan-Smith E; Rivera GK; Relling MV; Pui CH; Gajjar A
Cancer; 2008 May; 112(9):1983-91. PubMed ID: 18318429
[TBL] [Abstract][Full Text] [Related]
20. Phase III study of oral compared with intravenous topotecan as second-line therapy in small-cell lung cancer.
Eckardt JR; von Pawel J; Pujol JL; Papai Z; Quoix E; Ardizzoni A; Poulin R; Preston AJ; Dane G; Ross G
J Clin Oncol; 2007 May; 25(15):2086-92. PubMed ID: 17513814
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
